This cluster groups 2 independently calculated changes: Cash & equivalents increased 59.1%; Operating cash flow increased 0.3%.
2 evidence-backed components· Pharmaceutical Preparations
RESEARCH SNAPSHOTVERU INC.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents increased 59.1%; Operating cash flow increased 0.3%.
2 evidence-backed componentsCurrent assets changed +68.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
VERU · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-384430SEC ↗4Aug 17, 2026Period Aug 13, 20260001042167-26-000060SEC ↗10-QAug 10, 2026Period Jun 30, 20260001437749-26-026664SEC ↗8-KAug 10, 2026Period Aug 10, 20260001193125-26-341187SEC ↗8-KJul 2, 2026Period Jul 2, 20260001193125-26-294507SEC ↗8-KJun 4, 2026Period Jun 2, 20260001437749-26-019478SEC ↗10-QMay 13, 2026Period Mar 31, 20260001437749-26-016557SEC ↗8-KTransaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 13, 2026Filed Aug 17, 2026 | BARNETTE K GARYChief Scientific Officer | Open Market PurchaseDirect | 1,800 | $3 | $4,842 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Total assets changed +35.5% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Shares outstanding changed +16.4% from the comparable as-filed period. The change ranks at the 38th percentile of 8 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Research & development changed +44.1% from the comparable as-filed period.
Cash & equivalents changed +59.1% from the comparable as-filed period.
Stock-based compensation changed -65.4% from the comparable as-filed period.
Current ratio changed +82.5% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-220569